MDCO The Medicines Company

34.54
-0.03  -0%
Previous Close 34.57
Open 34.57
Price To book 17.53
Market Cap 2508965187
Shares 72,639,409
Volume 621,268
Short Ratio 13.02
Av. Daily Volume 1,321,274

SEC filingsSee all SEC filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 171018248
  2. 8-K - Current report 171016488
  3. SD - 17930264
  4. 8-K - Current report 17888287
  5. 8-K - Current report 17882689

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial to commence in 2017. Data due by end of 2019.
Inclisiran
Hypercholesterolemia
Development discontinued due to poor effiacy - November 7, 2016.
MDCO-216 - MILANO-PILOT
Acute coronary syndrome (ACS)
Approved August 29, 2017.
Meropenem-vaborbactam
Complicated urinary tract infections (cUTI)
CRL April 30 2014. Approved June 22 2015
Cangrelor
Reduction of thrombotic cardiovascular events including stent thrombosis in patients with coronary artery disease undergoing percutaneous coronary intervention (PCI)
Approved April 30, 2015.
RAPLIXA
Hemostasis
Approved April 30, 2015.
IONSYS
Acute postoperative pain
Approved August 6 2014 under priority review.
Oritavancin
ABSSSI

Latest News

  1. Vabomere: Major Addition to The Medicines Company’s Portfolio?
  2. The Medicines Company May See Improvement in Payer Access
  3. Inclisiran: Long-Term Growth Driver for The Medicines Company?
  4. Corbus Pharmaceuticals Appoints Paris Panayiotopoulos to Its Board of Directors
  5. The Medicines Company May Report Steep Revenue Decline in 2017
  6. Analysts’ Recommendations for The Medicines Company in October
  7. The Medicines Co. – Value Analysis (NASDAQ:MDCO) : October 13, 2017
  8. The Medicines Co. breached its 50 day moving average in a Bearish Manner : MDCO-US : October 12, 2017
  9. Should You Have The Medicines Company’s (MDCO) In Your Portfolio?
  10. The Medicines Company to Present New Data from TANGO II Study of VABOMERE™ (meropenem and vaborbactam) at IDWeek 2017
  11. ETFs with exposure to The Medicines Co. : October 4, 2017
  12. See what the IHS Markit Score report has to say about Medicines Co.
  13. The Medicines Company to Present Data at IDWeek 2017 on Infectious Disease Portfolio Including Recently Approved Antibiotic VABOMERE™ (meropenem and vaborbactam)
  14. The Medicines Co. breached its 50 day moving average in a Bullish Manner : MDCO-US : September 28, 2017
  15. Gene Therapy: A Big Week for Many Names
  16. The Medicines Co. Continues to Focus on Pipeline Development
  17. ETFs with exposure to The Medicines Co. : September 13, 2017
  18. The Medicines Co. :MDCO-US: Earnings Analysis: Q2, 2017 By the Numbers : September 11, 2017

SEC Filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 171018248
  2. 8-K - Current report 171016488
  3. SD - 17930264
  4. 8-K - Current report 17888287
  5. 8-K - Current report 17882689
  6. 8-K - Current report 17858658
  7. CT ORDER - Confidential treatment order 17841603
  8. CT ORDER - Confidential treatment order 17841540
  9. 10-Q - Quarterly report [Sections 13 or 15(d)] 17819037
  10. SC 13G - Statement of acquisition of beneficial ownership by individuals 17800695